Your browser doesn't support javascript.
loading
Patient and Caregiver Preferences for Hemophilia A Treatment in Taiwan: A Discrete Choice Experiment.
Chiou, Shyh-Shin; Weng, Te-Fu; Wang, Jiaan-Der.
Afiliación
  • Chiou SS; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • Weng TF; Department of Pediatrics, Chung Shan Medical University Hospital, Taichung City, Taiwan.
  • Wang JD; Center for Rare Disease and Hemophilia, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. Electronic address: wangjiaander@gmail.com.
Value Health Reg Issues ; 45: 101035, 2024 Aug 27.
Article en En | MEDLINE | ID: mdl-39197266
ABSTRACT

OBJECTIVES:

This study evaluated the treatment preferences among patients and caregivers for moderate or severe hemophilia A in Taiwan.

METHODS:

This cross-sectional study used a discrete choice experiment approach to assess treatment preferences among patients with hemophilia A and their caregivers. Respondents chose between 2 hypothetical treatments defined by 7 attributes including no bleeding episode, treated events of joint bleeding, long-term safety, type of treatment and risk of thromboembolic events, administration frequency, consumption route, and monitoring dosing options. Preference weights and relative importance (RI) of attributes were estimated using a hierarchical Bayesian logistic regression model.

RESULTS:

A total of 51 eligible respondents completed the discrete choice experiment (patients, 76.5%; caregivers, 23.5%). Most patients (70.6%) had severe hemophilia and 43.1% received prophylactic treatment for >10 years. Respondents valued "type of treatment and risk of thromboembolic events" as the most important factor (RI 26.2%; 95% CI 20.9-31.5) followed by "consumption route" (RI 25.8%; 95% CI 20.7-30.9) and "administration frequency" (RI 15.2%; 95% CI 12.0-18.4). "Monitoring dosing options" was the least important attribute (RI 6.3%; 95% CI 5.2-7.4). Respondents had 63% possibility to choose a treatment profile that has factor VIII product compared with nonfactor product.

CONCLUSIONS:

Patients and caregivers valued "type of treatment and risk of thromboembolic events" as the most important driver in choosing a treatment for moderate or severe hemophilia A. This study provides important insights into patients' preferences and informs clinicians to consider patients' choices when prescribing a treatment.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Value Health Reg Issues Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Value Health Reg Issues Año: 2024 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Estados Unidos